Canada markets open in 7 hours 11 minutes

Lucid Diagnostics Inc. (LUCD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7508-0.0457 (-5.74%)
At close: 04:00PM EDT
0.7694 +0.02 (+2.48%)
After hours: 05:44PM EDT

Lucid Diagnostics Inc.

360 Madison Avenue
25th Floor
New York, NY 10017
United States
917 813 1828
https://www.luciddx.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees70

Key Executives

NameTitlePayExercisedYear Born
Dr. Lishan Aklog M.D.Chairman & CEON/AN/A1966
Mr. Shaun M. O'Neill M.B.A.President & COON/AN/A1983
Mr. Dennis M. McGrath CPAChief Financial OfficerN/AN/A1957
Dr. Sanford D. Markowitz M.D., Ph.D.Cofounder & Strategic Advisor, Member of the Medical Advisor Board14.54kN/AN/A
Dr. Joseph Willis M.D.Cofounder, Strategic Advisor & Member of Medical Advisory BoardN/AN/AN/A
Dr. Amitabh Chak M.D.Cofounder, Strategic Advisor & Member of Medical Advisory BoardN/AN/AN/A
Richard D. YazbeckChief Technology OfficerN/AN/AN/A
Dr. Suman M. Verma M.D., Ph.D.Chief Scientific OfficerN/AN/AN/A
Dr. Brian J. deGuzman M.D.Chief Compliance OfficerN/AN/A1965
Mr. Michael Adam GordonGeneral Counsel & SecretaryN/AN/A1974
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Corporate Governance

Lucid Diagnostics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.